Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 4Not yet recruiting 3Withdrawn 1Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 32Rituximab 24zanubrutinib 19Vincristine 16fludarabine 14Prednisone 14Magnetic Resonance Spectroscopy 14venetoclax 13blinatumomab 13Specimen Handling 13Doxorubicin 13Bendamustine Hydrochloride 11obinutuzumab 10Lenalidomide 9Dexamethasone 9polatuzumab vedotin 8Methotrexate 8Biopsy 8glofitamab 7Prednisolone 7Cytarabine 7Radiotherapy 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Lisaftoclax × Lymphoid × Clear all
NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Sun Yat-sen University

Phase 1/2 Not yet recruiting
51 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07398638 2026-02-10

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Sun Yat-sen University

Phase 1/2 Not yet recruiting
122 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡